Sep. 4 at 11:37 AM
$ANVS p-Tau (Phosphorylated Tau, e.g., p-tau217 / p-tau181) Trajectory in AD vs. PD
Unlike NfL, which tracks general nerve cell damage, p-tau is a disease-specific marker for Alzheimer's pathology (amyloid and tau tangles).
Annual Progression Rates:
• Healthy Controls (Amyloid-Negative): ~1%–3%/yr. Baseline remains very low with minimal age-related accumulation.
• Alzheimer's (
$AD - Preclinical / MCI): ~10%–20%/yr. Rates surge dramatically as amyloid plaques trigger tau phosphorylation—often rising years before memory symptoms peak.
• Alzheimer's (
$AD - Dementia Phase): ~15%–25%+/yr. Reaches massive fold-increases over baseline during active disease progression.
• Parkinson's (
$PD - Pure/Typical): ~1%–3%/yr. Identical to healthy controls; p-tau does not elevate in typical PD.
• Parkinson's (
$PD with AD Co-pathology): ~8%–15%/yr. Levels only spike in PD patients who independently develop underlying Alzheimer's pathology alongside Lewy bodies.
